SPECIAL REPORT: How Will the Withdrawal of Generic Albuterol Change the U.S. Respiratory Disease Market?

Countries covered: United States Introduction: The albuterol inhaler market in the United States will soon change from low-value to signifi cant. The only MDIs sold will be branded HFA formulations; CFC propellants will be eliminated. Because the new HFA formulations are not bioequivalent, companies will compete for market leadership by convincing physicians and patients of their product's superiority and by making strategic pricing decisions. Questions Answered in This Spectrum Report: The imminent discontinuation of many generic formulations of albuterol in the United States will be the most signifi cant change in the respiratory disease market in some time. Will today's sales leaders weather the change and continue to enjoy market dominance? How will the change affect generics manufacturers? What marketing strategies will be key elements in development of the market between 2006 and 2011? What are the market leaders doing now? As production of albuterol CFC ends, patients will have to switch from familiar generics to more-expensive, branded HFA formulations that are not interchangeable despite having the same active ingredient. How can companies differentiate their products to win patient and physician allegiance? How will higher costs affect patients and reimbursement providers? How will they react? By the beginning of 2009, the U.S. market for inhaled albuterol MDIs will comprise branded products exclusively. Which products will drive the market at least until 2011? Which company is likely to own the biggest market share in 2011? Which companies will lose market share? Are new companies with new formulations likely to impact the market by 2011? Scope Respiratory disease market: asthma and chronic obstructive pulmonary disease prevalence and treatment; albuterol agents and manufacturers. Montreal Protocol: ban on CFC propellants; impact on the albuterol market and on brand and generic manufacturers, consumers, and payers. From CFC to HFA: supply and demand challenges; manufacturer compliance; non-bioequivalence of HFAs; reimbursement issues. Market outlook: continuing demand for albuterol products; DPI formulations; pricing and product differentiation; U.S. market forecast; winners and losers. Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Companies Mentioned in This Spectrum Report

3M
Amphastar
Andrx
Armstrong
AstraZeneca
Boehringer Ingelheim
Critical Therapeutics
Dava
Dey
GenPharm
GlaxoSmithKline
Ivax
Key Pharmaceutical
Merck
Novartis
Ono
Otsuka
Pliva
Schering-Plough
Sepracor
Teva
Warrick

More United States Respiratory/Pulmonary Reports

Epidemiology: COPD - Aging population and stable smoking rates to raise case numbers by Datamonitor
Introduction In 2010, Datamonitor estimates that there were about 69.5 million total prevalent cases of chronic obstructive pulmonary disease (COPD) in people aged over 40 in ...

Cystic Fibrosis by Global Industry Analysts
This report analyzes the US market for Cystic Fibrosis in Millions of US$. Annual estimates and forecasts are provided for the period of 2007 through ...

U.S. Sleep Apnea Diagnostic and Therapeutic Devices Markets by Frost & Sullivan
This research service analyzes market trends in the U.S. sleep apnea diagnostic and therapeutic devices market since 2005, predicts future changes in market measurements through ...

Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections) by Kalorama Information
A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours ...

The U.S. Sleep Market by Marketdata Enterprises Inc.
Of a total population of 305 million Americans, 58% are estimated to experience insomnia symptoms or sleep disorders. Companies across America are trying to sell ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>